Beclomethasone Shortage: What Providers and Prescribers Need to Know in 2026

Qvar RediHaler (Beclomethasone Dipropionate HFA) is not on the FDA's drug shortage list as of 2026. However, pharmacy-level stock-outs are being reported intermittently across the country, and prescribers are fielding calls from patients who cannot fill their prescriptions. This briefing covers what you need to know for clinical decision-making.

Current Availability Status

FDA shortage list: Not listed as of 2026

ASHP tracking: Not classified as an active shortage

Real-world availability: Inconsistent. Pharmacy-level stock-outs reported especially in chain pharmacies; independent and specialty pharmacies may have better availability

Manufacturer: Teva Pharmaceuticals (Norton Waterford, Ireland) — sole U.S. supplier

Generic status: No generic approved; device patents expire ~May 2031

Why Supply Is Inconsistent: Clinical Context

The cascade began with the ICS market disruption of 2023-2024. GSK's discontinuation of brand-name Flovent (Fluticasone Propionate HFA/Diskus) in January 2024 shifted significant prescribing volume toward remaining ICS agents. Simultaneously, Budesonide inhalation suspension entered an active ASHP-tracked shortage. Qvar RediHaler absorbed a portion of that demand increase — and as the sole-source, no-generic product that it is, even modest demand increases create distribution strain.

Additionally, Asmanex (Mometasone) has experienced its own supply issues since 2024. With multiple ICS agents facing challenges, Qvar has found itself in higher demand than it was designed to handle under single-manufacturer conditions.

Pharmacological Considerations Before Switching

Beclomethasone Dipropionate HFA (Qvar RediHaler) has two clinically important distinguishing features providers should factor into switching decisions:

1. Ultra-fine particle formulation. Qvar uses HFA propellant to deliver extra-fine particles (MMAD ~1.1 microns), achieving significantly higher small-airway and peripheral lung deposition than conventional CFC-based or DPI inhalers. This means dose equivalences with conventional ICS agents are not straightforward and require downward adjustment when switching to most alternatives.

2. Esterase metabolism, not CYP3A4. Beclomethasone is activated by esterase hydrolysis to its active metabolite 17-BMP. Unlike Fluticasone Propionate and Budesonide — which are extensively metabolized by CYP3A4 — Beclomethasone has a favorable interaction profile for patients on strong CYP3A4 inhibitors (ritonavir, cobicistat, ketoconazole, itraconazole). If switching a patient who is on a CYP3A4 inhibitor, carefully review the ICS choice.

ICS Dose Equivalence When Switching Off Beclomethasone

These are approximate equivalences based on published ICS dose-equivalence tables. Individual patient response, disease severity, and inhaler technique should guide final dosing decisions:

Qvar 80 mcg BID ≈ Fluticasone Propionate HFA 110 mcg BID (low-to-medium dose range)

Qvar 160 mcg BID ≈ Fluticasone Propionate 220 mcg BID

Qvar 320 mcg BID ≈ Fluticasone Propionate 440 mcg BID (high dose)

Always step patients up or down based on asthma control assessment after the switch. Qvar's ultra-fine particle formulation may have provided benefit in small airways that a conventional ICS switch at equivalent nominal doses does not replicate.

Recommended Therapeutic Alternatives

Generic Fluticasone Propionate HFA (multiple manufacturers): Most widely available alternative. 44, 110, and 220 mcg strengths. Not appropriate for patients on strong CYP3A4 inhibitors. Cash price $30-$80 with discount coupons.

Budesonide/Formoterol (generic Symbicort / Breyna): If patient has been on Qvar monotherapy but needs ICS/LABA, this combination is widely available as of 2026. Cash price $90-$150 with coupons.

Ciclesonide (Alvesco): Preferred for patients with history of oral candidiasis on other ICS agents. Prodrug activated in lung tissue. Once or twice daily dosing. Low oropharyngeal side effect profile.

Mometasone (Asmanex HFA/Twisthaler): Once-daily dosing; also available as ICS/LABA Dulera (mometasone/formoterol). Note: Asmanex itself has had supply issues in 2025-2026, particularly the Twisthaler 220 mcg/30-dose presentation.

Insurance and Prior Authorization Implications

Qvar RediHaler is typically listed as Tier 3 (preferred brand) on most commercial formularies. If switching to an alternative, be aware:

Generic Fluticasone HFA may require a new prescription and potentially a prior authorization if the formulary requires step therapy

Some plans offer lower formulary tier placement for generic Fluticasone, making it more cost-effective for patients

For patients who specifically need the breath-actuated device (hand-breath coordination issues), document clinical necessity to support formulary exceptions or prior authorization for Qvar

How to Help Your Patients Find Beclomethasone

Direct patients to medfinder for providers to help them locate pharmacies with stock near them. For a detailed workflow guide, see how to help your patients find Beclomethasone in stock.